Simon Bornschein

Simon Bornschein has extensive work experience in the field of biopharmaceuticals and immunology. Simon is currently the Founder & CEO of coding.bio, a position they have held since December 2020. Prior to this, they worked as a CAR-T engineer at Quell Therapeutics from February 2020 to November 2020. Simon also served as a Scientist at Celyad, a clinical-stage biopharmaceutical company, where they focused on the development of CAR T-cell therapies. Simon'srole involved engineering novel CAR-T receptors and targets. Before joining Celyad, Simon worked as a Doctoral Researcher in cancer immunology at VIB from January 2013 to November 2017. During this time, they conducted research projects on acute lymphoblastic leukemia (ALL) and the T cell activation pathway. Simon began their career as a Graduate Researcher at the University of Basel, where they worked on the genetic and epigenetic control of thymic epithelial cell development and function. Overall, Simon's work experience demonstrates their expertise in biopharmaceutical research and development, with a focus on cancer immunology and CAR-T therapies.

Simon Bornschein has a strong educational background in the field of immunology and biochemistry. Simon obtained their Bachelor of Science degree with a major in Biochemistry from Leibniz Universität Hannover in 2009. Following that, they pursued further studies and completed a Bachelor of Science degree in Biochemistry at Université de Fribourg - Universität Freiburg from 2009 to 2011.

Driven by their interest in immunology, Simon then pursued a Master of Science degree in Immunology at the University of Basel from 2011 to 2012. Simon continued to expand their knowledge in this field and embarked on a doctoral program at KU Leuven, where they earned their Doctor of Philosophy (Ph.D.) in Immunology between 2013 and 2017.